GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » United Laboratories International Holdings Ltd (FRA:UNJ) » Definitions » Piotroski F-Score

United Laboratories International Holdings (FRA:UNJ) Piotroski F-Score : 7 (As of Apr. 28, 2024)


View and export this data going back to 2007. Start your Free Trial

What is United Laboratories International Holdings Piotroski F-Score?

Good Sign:

Piotroski F-Score is 7, indicates a very healthy situation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

United Laboratories International Holdings has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

The historical rank and industry rank for United Laboratories International Holdings's Piotroski F-Score or its related term are showing as below:

FRA:UNJ' s Piotroski F-Score Range Over the Past 10 Years
Min: 4   Med: 7   Max: 8
Current: 7

During the past 13 years, the highest Piotroski F-Score of United Laboratories International Holdings was 8. The lowest was 4. And the median was 7.


United Laboratories International Holdings Piotroski F-Score Historical Data

The historical data trend for United Laboratories International Holdings's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

United Laboratories International Holdings Piotroski F-Score Chart

United Laboratories International Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.00 8.00 7.00 7.00 -

United Laboratories International Holdings Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.00 - 7.00 - -

Competitive Comparison of United Laboratories International Holdings's Piotroski F-Score

For the Drug Manufacturers - Specialty & Generic subindustry, United Laboratories International Holdings's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


United Laboratories International Holdings's Piotroski F-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, United Laboratories International Holdings's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where United Laboratories International Holdings's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec22) TTM:Last Year (Dec21) TTM:
Net Income was €214 Mil.
Cash Flow from Operations was €275 Mil.
Revenue was €1,535 Mil.
Gross Profit was €673 Mil.
Average Total Assets from the begining of this year (Dec21)
to the end of this year (Dec22) was (2269.172 + 2569.928) / 2 = €2419.55 Mil.
Total Assets at the begining of this year (Dec21) was €2,269 Mil.
Long-Term Debt & Capital Lease Obligation was €149 Mil.
Total Current Assets was €1,695 Mil.
Total Current Liabilities was €952 Mil.
Net Income was €137 Mil.

Revenue was €1,348 Mil.
Gross Profit was €585 Mil.
Average Total Assets from the begining of last year (Dec20)
to the end of last year (Dec21) was (1880.962 + 2269.172) / 2 = €2075.067 Mil.
Total Assets at the begining of last year (Dec20) was €1,881 Mil.
Long-Term Debt & Capital Lease Obligation was €32 Mil.
Total Current Assets was €1,388 Mil.
Total Current Liabilities was €908 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

United Laboratories International Holdings's current Net Income (TTM) was 214. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

United Laboratories International Holdings's current Cash Flow from Operations (TTM) was 275. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec21)
=214.087/2269.172
=0.09434587

ROA (Last Year)=Net Income/Total Assets (Dec20)
=137.294/1880.962
=0.07299137

United Laboratories International Holdings's return on assets of this year was 0.09434587. United Laboratories International Holdings's return on assets of last year was 0.07299137. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

United Laboratories International Holdings's current Net Income (TTM) was 214. United Laboratories International Holdings's current Cash Flow from Operations (TTM) was 275. ==> 275 > 214 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=148.902/2419.55
=0.0615412

Gearing (Last Year: Dec21)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec20 to Dec21
=31.727/2075.067
=0.01528963

United Laboratories International Holdings's gearing of this year was 0.0615412. United Laboratories International Holdings's gearing of last year was 0.01528963. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec22)=Total Current Assets/Total Current Liabilities
=1694.581/952.304
=1.77945383

Current Ratio (Last Year: Dec21)=Total Current Assets/Total Current Liabilities
=1387.579/908.058
=1.5280731

United Laboratories International Holdings's current ratio of this year was 1.77945383. United Laboratories International Holdings's current ratio of last year was 1.5280731. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

United Laboratories International Holdings's number of shares in issue this year was 1819.73. United Laboratories International Holdings's number of shares in issue last year was 1840.043. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=672.824/1534.711
=0.43840436

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=585.116/1348.271
=0.43397507

United Laboratories International Holdings's gross margin of this year was 0.43840436. United Laboratories International Holdings's gross margin of last year was 0.43397507. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec21)
=1534.711/2269.172
=0.67633084

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec20)
=1348.271/1880.962
=0.71679864

United Laboratories International Holdings's asset turnover of this year was 0.67633084. United Laboratories International Holdings's asset turnover of last year was 0.71679864. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+1+0+1+1+1+0
=7

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

United Laboratories International Holdings has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

United Laboratories International Holdings  (FRA:UNJ) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


United Laboratories International Holdings Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of United Laboratories International Holdings's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


United Laboratories International Holdings (FRA:UNJ) Business Description

Traded in Other Exchanges
Address
No. 6 Fuk Wang Street, Yuen Long Industrial Estate, New Territories, Hong Kong, HKG
United Laboratories International Holdings Ltd is a major drug manufacturing company. United Laboratories is organized into three revenue streams, including Intermediate products, Bulk medicine, and Finished products. The company's Finished products segment includes antibiotic products, insulin series products, and other medicines. The vast majority of the company's revenue is derived from its Bulk medicine segment, followed by Finished products. Most of the company's sales are generated in China, followed by Europe and India.

United Laboratories International Holdings (FRA:UNJ) Headlines

No Headlines